Recent studies have suggested that low SLC39A1 [15], SLC39A2 and SLC39A3 [16] expression in prostate cancer, low SLC39A3 [17] and high SLC39A4 [18] expression in pancreatic cancer. This evidence concerns the gene SLC39A4 and prostate cancer.